We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03537482
Recruitment Status : Recruiting
First Posted : May 25, 2018
Last Update Posted : August 16, 2022
Information provided by (Responsible Party):
Ascentage Pharma Group Inc.

Brief Summary:
This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.

Condition or disease Intervention/treatment Phase
Hematologic Malignancies Drug: APG-2575 Early Phase 1

Detailed Description:
APG-2575 will be administered orally, once daily for consecutive 4 weeks as one cycles. Initially, the start dose is 20mg. Single patient cohorts will be evaluated, the dose of APG-2575 will be increased in subsequent cohorts, to 50 mg, 100 mg, 200 mg, 400 mg, 600mg and 800mg accordingly. If there is any one of the following event is observed, a DLT, two drug related Grade 2 toxicities or one drug related ≥ Grade 3 toxicity, or laboratory or clinical TLS, or suspected hypersensitivity reaction occur in Cycle 1, or dose level of 400 mg is reached, the dose escalation will convert to the standard 3+3 design, If ≥ 2/6 patients develop DLT at any dose level dose escalation will cease and the dose level immediately below will be expanded to 6 patients. If ≤ 1/6 patients develop a DLT at the highest dose reached this will be declared the MTD. After the MTD is defined, a maximum of 20 patients will be treated at that dose level.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: dose escalation and dose expansion after MTD
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies
Actual Study Start Date : August 7, 2018
Estimated Primary Completion Date : September 15, 2022
Estimated Study Completion Date : February 15, 2023

Arm Intervention/treatment
Experimental: single-agent, open-label, Phase I study of APG-2575
The study consists of the dose escalation stage and the dose expansion stage
Drug: APG-2575
APG-2575 will be administered as an oral tablet

Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) [ Time Frame: 28 days ]
    Patients with APG-2575 treatment related adverse events (AE), serious adverse events (SAE) will be assessed according NCI CTCAE Version 4.0

Secondary Outcome Measures :
  1. Maximum plasma concentration (Cmax) [ Time Frame: 28 days ]
    Maximum plasma concentration (Cmax) will be assessed in the patients treated with APG-2575

  2. Area under the plasma concentration versus time curve (AUC) [ Time Frame: 28 days ]
    Area under the plasma concentration versus time curve (AUC) of APG-2575 will be assessed in the patients treated with APG-2575

  3. Anti-tumor effects of APG-2575 [ Time Frame: up to 2 years ]
    Response will be evaluated every 2 cycles (8 weeks), by the investigator based on disease specific criteria.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age ≥18 years old.
  2. Histologically confirmed diagnosis of either one of the B-cell hematologic malignancies including multiple myeloma, chronic lymphocytic leukemia, lymphoplasmacytic lymphoma, and non-Hodgkin's lymphoma such as mantle cell lymphoma, diffuse large B cell lymphoma, Waldenstrom macroglobulinemia (WM) and acute myeloid leukemia
  3. Patient must have relapsed or refractory to, intolerant to, or are considered ineligible for therapies known to provide clinical benefit. In addition,

    a. AML Patients will be eligible if they have failed standard induction regimen, are not considered candidate for further chemotherapy or stem cell transplantation or have primary refractory AML.

  4. Life expectancy ≥ 3 months.
  5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 -1 in dose escalation ; 0-2 in dose expansion.
  6. QTc interval ≤450ms in males, and ≤470ms in females.
  7. Adequate bone marrow function independent of growth factor:
  8. Absolute neutrophil count (ANC) ≥1.0 X 109/L.
  9. Hemoglobin ≥ 8.0 g/dL.
  10. Platelets count ≥ 30 X 109/L (entry platelet count must be independent of transfusion within 7 days of first dose).
  11. Adequate renal and liver function as indicated by:

Exclusion Criteria:

Patients who meet any of the following exclusion criteria are not to be enrolled in this study:

  1. Prior history of allogeneic cell transplant.
  2. Subjects have been diagnosed with Burkitt's lymphoma, Burkitt-like lymphoma, or lymphoblastic lymphoma/leukemia.
  3. Received chemotherapy within 14 days (42 days for nitrosoureas or mitomycin C) prior to entering the study.
  4. Received biologic (< 28 days), small molecule targeted therapies (< 5 half-life) or other anti-cancer therapy within 21 days of study entry.
  5. Radiation within 14 days of study entry, thoracic radiation within 28 days of study entry.
  6. Has gastrointestinal conditions that could affect the absorption of APG-2575 in the opinion of the Investigator.
  7. Has known active central nervous system (CNS) involvement.
  8. Continuance of toxicities due to prior radiotherapy or chemotherapy agents that do not recover to ≤ Grade 1 except alopecia or neuropathy.
  9. Concurrent treatment with an investigational agent, 14 days for small molecular agents and/or 28 days for biologics treatment prior to the first dose of therapy.
  10. Failure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients with active wound healing, patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry.
  11. Unstable angina, myocardial infarction, or a coronary revascularization procedure within 180 days of study entry.
  12. Active rheumatoid arthritis (RA), active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation.
  13. Active infection requiring systemic antibiotic/ antifungal medication, known clinically active hepatitis B or C infection, or on antiretroviral therapy for HIV disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03537482

Layout table for location contacts
Contact: Laura Glass 301-520-5964 Laura.Glass@ascentage.com

Layout table for location information
United States, Florida
Mayo Clinic Recruiting
Jacksonville, Florida, United States, 32224
Contact: Sikander Ailawadhi, MD    904-953-0853    s.ailawadhi@mayo.org   
Principal Investigator: sikander ailawdhi, md         
United States, North Carolina
Duke Unviersity Recruiting
Durham, North Carolina, United States, 27701
Contact: danielle brander, MD    919-684-8000    dbrander@duke.edu   
Principal Investigator: Danielle Brander, MD         
United States, Texas
MDACC Recruiting
Houston, Texas, United States, 77030
Contact: Tapan Kadia, MD    713-792-7734    tkadia@mdanderson.org   
Principal Investigator: Tapan Kadia, MD         
Australia, Victoria
St. Vincent Hospital Recruiting
Fitzroy, Victoria, Australia, 3065
Contact: lisa demosthenous    61-3-9231-3630    lisa.demosthenous@suha.org.au   
Principal Investigator: Masa Lasica, MD         
Epworth Healthcare Recruiting
Richmond, Victoria, Australia, 3121
Contact: andrew Karapetis, MD    37-817-7762    a.karapetis@epworth.au.com   
Principal Investigator: Costas Yannakou, MD         
Sponsors and Collaborators
Ascentage Pharma Group Inc.
Layout table for investigator information
Study Chair: Yifan Zhai, MD, PhD Ascentage Pharma Group Inc.
Layout table for additonal information
Responsible Party: Ascentage Pharma Group Inc.
ClinicalTrials.gov Identifier: NCT03537482    
Other Study ID Numbers: APG2575-001
First Posted: May 25, 2018    Key Record Dates
Last Update Posted: August 16, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematologic Neoplasms
Neoplasms by Site
Hematologic Diseases